BRINGING NOVEL siRNA DRUGS INTO THE CLINIC

Argonaute RNA Ltd. is developing safe and reliable methods of temporarily silencing target genes in different tissue cells.

  • Our mission is to bring novel siRNA drugs into the clinic
  • Our aim is to develop a pipeline of new Argonaute siRNA drugs by a sequence of collaboration deals with pharma partners
  • Our vision is to make Argonaute a UK leader in the gene silencing field

ARGONAUTE SCIENCE

Argonaute RNA is pursuing a number of therapeutic opportunities in RNA interference. RNAi harnesses a cell mechanism that inhibits the expression of a specific gene and thereby inhibits the production of a specific protein.

Argonaute RNA research projects build on existing intellectual property. We show how our proprietary modification of small interfering RNA (siRNA) allows safe and effective ways to silence specific gene expression.

We use a novel method of stabilising the siRNA and thereby avoid a range of issues which have hitherto proved significant obstacles to developing siRNA drugs for use in man.

A scalable, platform-technology that reduces costs, improves safety and accelerates development timelines to treat diseases amenable to temporary gene silencing

– Anthony Parker

WHO WE ARE

EXECUTIVE LEADERSHIP TEAM

RICHARD TOMPKINS
RICHARD TOMPKINSChief Financial Officer
DAN MITCHELL
DAN MITCHELLChief Scientific Officer
ANTHONY PARKER
ANTHONY PARKERExecutive Chairman
MIKE KHAN
MIKE KHANChief Executive Officer

ARGO TEAM

ROB DOCHERTY
ROB DOCHERTYNon-Executive Director
PAMELA PENATTA
PAMELA PENATTALead Biomolecular Scientist
GERDA GASIUNAITE
GERDA GASIUNAITEMolecular Biologist
STELLA PELENGARIS
STELLA PELENGARISChief Medical Officer
 JOHN MATLOCK
JOHN MATLOCKNon-Executive Director
TBD
TBDTBD
MARK EDBROOKE
MARK EDBROOKEHead of Translational Research
ALEX PATERSON
ALEX PATERSONHead of data science

BOARD OF DIRECTORS

  • CoFounder/Chairman – Anthony Parker
    • Anthony co-founded Argonaute RNA Ltd in 2015.
      He is responsible for chairing meetings of the science team and co-ordinating engagement with third party research service providers.
      His background is in finance and has worked for thirty years in investment banking and fund management. He has extensive experience in biotech, including as non-executive director of an immunotherapy company listed on the AIM market of the LSE.
  • CEO – Dr Mike Khan
    • Mike is the former CMO of Silence Therapeutics plc, and has over 25 years of experience as a leader in R&D, spanning the full spectrum of preclinical, translational and clinical development. Mike is Former Head of Molecular Medicine and Associate Professor of Medicine at the University of Warwick. He also leads one of the foremost cardio metabolic clinics in the UK, based at the University Hospitals of Coventry and Warwickshire NHS Trust. He is an expert advisor to NICE and the EC and has contributed to establishing the current state of the art for treatment and prevention of cardiovascular diseases in the UK
  • CoFounder/CFO – Dr Richard Tompkins
    • Richard co-founded Argonaute RNA Ltd with Anthony in 2015.
      Richard leads on guiding all R&D projects from planning to implementation to meet intellectual property objectives. Formerly a Royal Marines officer, Richard has seventeen years of investment banking and consultancy experience, latterly at Citigroup and Barclays. He has a PhD in Economics from Exeter.

INVESTORS

Argonaute RNA Ltd. is backed by a network of high net worth investors. For EIS opportunities, please contact info@argonauterna.com or use the submission form below.

CONTACT US 

Argonaute RNA Ltd. is located in Bristol City Centre. Please get in touch if you need further information on our company or the scientific research it funds.


    Argonaute RNA Ltd.

    Science Creates (St Philips)
    Albert Road
    Bristol BS2 0XJ
    United Kingdom

    Call: +44 (0)117 974 2561
    Email: info@argonauterna.com

    Google Maps

    Get directions with Google Maps

    Share On Social Media